About This Page
This is a clinician-written, evidence-based summary aligned to the 2026 MLA Content Map. It is intended for medical students and junior doctors preparing for the UKMLA. Always cross-reference with NICE guidance, local protocols, and clinical judgement.
Key points
- Features of BOTH schizophrenia (positive/negative symptoms) AND mood disorder (mania or depression) occurring simultaneously
- Key diagnostic criterion: psychotic symptoms must occur for ≥2 weeks in the ABSENCE of prominent mood symptoms (distinguishes from bipolar with psychosis)
- Two subtypes: bipolar type (manic + psychotic episodes) and depressive type (depressive + psychotic episodes)
- Management: antipsychotic (as per schizophrenia) + mood stabiliser (lithium or valproate) or antidepressant (for depressive type)
- Prognosis intermediate between schizophrenia (worse) and bipolar disorder (better)
- Managed under NICE CG178 (psychosis/schizophrenia) and CG185 (bipolar) depending on predominant features
Overview
Schizoaffective disorder occupies a diagnostic space between schizophrenia and bipolar disorder. It is characterised by episodes that simultaneously meet criteria for both a mood episode (manic, mixed, or major depressive) and schizophrenia-like psychotic symptoms (delusions, hallucinations, disorganised speech, negative symptoms). Crucially, psychotic symptoms must also be present for at least 2 weeks in the absence of prominent mood symptoms during the overall illness course — this distinguishes schizoaffective disorder from mood disorders with psychotic features. Two subtypes are recognised: bipolar type (manic episodes are part of the presentation) and depressive type (only depressive episodes occur alongside psychosis).
Epidemiology
Schizoaffective disorder is less common than both schizophrenia and bipolar disorder, with an estimated lifetime prevalence of 0.3%. It is more common in women. Age of onset is typically early adulthood. The disorder shares genetic risk factors with both schizophrenia and bipolar disorder, supporting its conceptualisation as a spectrum condition. Prognosis is generally intermediate — better than schizophrenia but worse than pure bipolar disorder, with better social functioning and fewer negative symptoms than schizophrenia.
Clinical Features
Symptoms
Psychotic symptoms: delusions, hallucinations (auditory most common), disorganised thinking — as per schizophrenia
Manic symptoms (bipolar type): elevated mood, grandiosity, reduced sleep, pressured speech, disinhibition
Depressive symptoms (depressive type): low mood, anhedonia, hopelessness, suicidal ideation
Psychotic symptoms occurring INDEPENDENTLY of mood episodes — present for ≥2 weeks without mood disturbance
Negative symptoms may be present but are typically less prominent than in schizophrenia
Suicidal ideation — significant risk, particularly during depressive episodes
Signs
Combination of psychotic and mood features on MSE
Variable presentation depending on whether in manic, depressive, or psychotic phase
May have better rapport and social function than schizophrenia patients
Investigations
First-line
Clinical assessment (MSE)Longitudinal history is essential — establish whether psychotic symptoms occur independently of mood episodes
Collateral historyFamily/carer input to map the temporal relationship between psychotic and mood symptoms over multiple episodes
Second-line
Bloods and drug screenAs per schizophrenia: FBC, TFTs, U&Es, glucose, lipids, UDS — exclude organic and substance-induced causes
Specialist
Longitudinal follow-upDiagnosis often refined over time — requires observation across multiple episodes to confirm pattern
1
Acute management
- Antipsychotic for psychotic symptoms: as per schizophrenia (risperidone, olanzapine, aripiprazole, quetiapine)
- If manic: add mood stabiliser (lithium or valproate) or antipsychotic with antimanic properties
- If depressive: consider cautious antidepressant WITH antipsychotic cover (avoid precipitating mania)
2
Long-term prophylaxis
- Combination of antipsychotic + mood stabiliser is typically required
- Lithium for mood episode prevention (monitor as per bipolar guidelines)
- Continue antipsychotic long-term to prevent psychotic relapse
- Lamotrigine if depressive episodes predominate
3
Psychosocial interventions
- CBTp and family intervention as per schizophrenia guidelines
- Psychoeducation about the illness and treatment
- Supported employment, social skills training, relapse prevention planning
Complications
- Suicide: Significant risk — particularly during depressive episodes
- Substance misuse: Common comorbidity
- Metabolic complications: From antipsychotic and mood stabiliser treatment
- Diagnostic instability: Diagnosis may change over time as more episodes are observed
- Functional impairment: Intermediate between schizophrenia and bipolar — may maintain some social function
UKMLA Exam Tips
- 1Key differentiator from bipolar with psychosis: psychotic symptoms must occur for ≥2 weeks WITHOUT mood disturbance
- 2Key differentiator from schizophrenia: prominent mood episodes (mania or depression) are part of the illness
- 3Bipolar with psychotic features: psychosis ONLY during mood episodes. Schizoaffective: psychosis ALSO between mood episodes
- 4Prognosis: better than schizophrenia, worse than bipolar disorder
- 5Treatment often requires dual therapy: antipsychotic + mood stabiliser
- 6Diagnosis often changes — longitudinal follow-up over multiple episodes is needed for diagnostic certainty
Put your reading into practice
Topic-specific question practice is not linked for this article yet.
Choose UKMLA questions from the existing bank. General exam practice covers your selected topics; it is not filtered to this article. Your usual question-bank access applies.
Choose UKMLA practiceAfter your session, return to this section to revisit the reading and choose your next review.
Verified Sources & References
related resources
Save your place and choose what comes next
Psychiatry · Article 10 of 25